FSSAI said three separate adjudication cases have been filed against Nestlé India in connection with the products.
The regulator said claims relating to “5 HMOs” and “Whey Protein” were found on promotional material for NAN Excella Pro Stage 1, while Lactogen Pro 1 carried a claim that its protein was “easy to digest”.
FSSAI said the action followed its examination of the infant nutrition products and promotional material available on e-commerce platforms. The regulator also said it sought clarifications from Nestlé India regarding the claims identified on the products.
“In NAN Excella Pro Stage 1, claims relating to “5 HMOs” and “Whey Protein” were observed, while in Lactogen Pro 1, a claim relating to “Whey Protein” being easy to digest was observed. Accordingly, clarifications were sought from M/s Nestlé India Limited regarding the above claims. Both products were found to be in contravention of Regulation 4(2) of the FSS (Foods for Infant Nutrition) Regulations, 2020, which restricts promotional claims/material intended to increase the saleability of of infant foods, and Section 3 of the IMS Act, 1992, which prohibits their advertisement and promotion,” said FSSAI in a statement.
Also read: Supreme Court allows all co-location cases to be settled between SEBI and NSE
Separately, FSSAI said a sample of follow-up formula manufactured by Nestlé India was found to be sub-standard during laboratory analysis with respect to its biotin content.
The sample was subsequently referred for re-analysis. The Referral Laboratory also found the sample to be non-conforming with the prescribed biotin requirement under the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020.Nestlé India shares fell 2.46% to ₹1,336.90 on Friday, following the FSSAI’s action against the company.
(Edited by : Sheersh Kapoor)
First Published: Sept 18, 2026 2:16 PM IST
